Eton Pharmaceuticals, Inc. reported that Chief Business Officer David Krempa received a grant of 128,985 performance-vested restricted stock units on July 31, 2026 under the 2018 equity incentive plan. Each unit may convert into one share of common stock if the closing price reaches $72.36 per share for one trading day before the third anniversary of the grant; otherwise the entire award is forfeited without consideration on July 31, 2029. The 128,985 units represent the maximum and only number of shares issuable under this award.
MAIER PAUL V reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Paul V Maier received a grant of 10,000 performance-vested restricted stock units on July 31, 2026 under the company’s 2018 equity incentive plan. Each unit equals one share and vests in full if the stock’s closing price reaches $72.36 for one trading day before July 31, 2029; otherwise the award is forfeited. After the grant, he holds 10,000 units, the maximum and only number of shares issuable under this award.
RIEDEL NORBERT G reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Norbert G. Riedel received a grant of 10,000 performance-vested restricted stock units (RSUs) on July 31, 2026 under the 2018 equity incentive plan. Each RSU represents one common share and vests in full if the stock’s closing price reaches $72.36 or higher for one trading day before July 31, 2029; otherwise the entire award is forfeited. Following this grant, Riedel holds 10,000 such units.
Adams Jennifer McKie reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Jennifer McKie Adams received a grant of 10,000 performance‑vested restricted stock units under the 2018 equity incentive plan. Each unit represents one share, vesting only if the stock closes at $72.36 or higher for one trading day before July 31, 2029; otherwise the award is forfeited.
Eton Pharmaceuticals, Inc. appointed Danka Radosavljevic, age 42, as Chief Operating Officer on July 31, 2026. She has been with the company since 2017 and most recently served as Executive Vice President, Operations overseeing quality, product development, regulatory, supply chain and information systems.
Her compensation package includes an annual base salary of $520,800 and an annual discretionary incentive bonus with a target of 50% of base salary, contingent on corporate and/or individual performance targets to be approved by the Board of Directors.
Eton Pharmaceuticals reported submitting a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration to expand the indication of KHINDIVI (hydrocortisone) oral solution to younger pediatric patients. The new KHINDIVI formulation showed bioequivalence to ALKINDI SPRINKLE, an FDA-approved hydrocortisone granule formulation.
KHINDIVI is currently approved as replacement therapy for pediatric patients 5 years of age and older with adrenocortical insufficiency and is the only FDA‑approved oral hydrocortisone solution. Management comments that label expansion could potentially occur in the first half of 2027. Eton estimates approximately 10,000 pediatric adrenal insufficiency patients in the U.S. and highlights extensive safety warnings, including risks of adrenal crisis, hyperosmolarity, metabolic acidosis, growth retardation, Cushing’s syndrome, bone density loss, psychiatric effects, ophthalmic and gastrointestinal adverse reactions.
BlackRock, Inc. reports beneficial ownership of 1,882,410 shares of Eton Pharmaceuticals, Inc. common stock, representing 6.9% of the class as of June 30, 2026. These holdings are attributed to certain business units of BlackRock and its subsidiaries.
BlackRock has sole voting power over 1,850,186 shares and sole dispositive power over 1,882,410 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Eton’s outstanding common shares.
Eton Pharmaceuticals, Inc. ten percent owner Opaleye Management Inc., through a separately managed account and Opaleye, L.P., reported selling a total of 28,315 common shares on July 14, 2026 at a weighted average price of $37.5431 per share. After these indirect sales, the accounts held 40,000 and 2,665,000 shares, respectively, with Opaleye Management disclaiming beneficial ownership except for its pecuniary interest. The amendment states Opaleye Management is no longer subject to Section 16 reporting.
Opaleye Management Inc., a more-than-10% holder of Eton Pharmaceuticals, reported open-market sales totaling 28,315 shares of common stock on July 14, 2026 at a weighted average price of $37.5431 per share. The sales consisted of 13,315 shares held in a separately managed account and 15,000 shares held by Opaleye, L.P. Following these transactions, the managed account held 40,000 shares and Opaleye, L.P. held 2,665,000 shares, all reported as indirect holdings. Opaleye Management may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Eton Pharmaceuticals, Inc. President & CEO Sean Brynjelsen reported only equity acquisitions. He exercised employee stock options covering 200000.0000 shares of common stock at an exercise price of 1.3700 on July 14, 2026, and converted 27500.0000 shares from restricted stock units on July 12, 2026. After these derivative exercises, he directly holds 1061194.0000 common shares, with no sales, gifts, or tax-withholding dispositions reported.